JLE

Sang Thrombose Vaisseaux

MENU

Arterial thrombosis and genetic blood clotting anomalies Volume 12, issue 7, Août - Septembre 2000

Figures

See all figures

Authors
  • Page(s) : 417-25
  • Published in: 2000

The value of antithrombotic agents in the treatment and prevention of acute ischaemia is well established. The proteins of blood clotting (related to the endothelium, the platelets and clotting factors) play an important part in the physiopathology of atherosclerosis and in its different presentations. The genes coding these proteins are, therefore, possible candidates for atherothrombotic pathology. Many studies have shown that plasma concentrations of certain clotting factors (fibrinogen, factor VII and PAI-1) are raised in patients with arterial disease. However, clinical studies of known genetic polymorphisms of these factors have provided contradictory results. With respect to platelets, the study of integrin genetic polymorphism, especially of the glycoprotein IIbIIIa, showed no relationship to arterial disease. Hyperhomocysteinaemia has been correlated with myocardial infarction, cerebral ischaemic events and peripheral arterial disease. However, the implication of the thermolabile C677T of MTHFR could not be demonstrated. Tables summarising the different studies named in this article with numbers of cases and main results are accessible on the internet site: http://www.john-libbey-eurotext.fr/fr/revues/stv/index.htm.